Safety and Effectiveness of Meropenem in Infants With Suspected or Complicated Intra-abdominal Infections by Cohen-Wolkowiez, Michael et al.
M A J O R A R T I C L E
Safety and Effectiveness of Meropenem in
Infants With Suspected or Complicated
Intra-abdominal Infections
Michael Cohen-Wolkowiez,1,2 Brenda Poindexter,3 Margarita Bidegain,1 Joern-Hendrik Weitkamp,4
Robert L. Schelonka,5 David A. Randolph,6 Robert M. Ward,7 Kelly Wade,8 Gloria Valencia,9 David Burchfield,10
Antonio Arrieta,11 Varsha Mehta,12 Michele Walsh,13 Anand Kantak,14 Maynard Rasmussen,15 Janice E. Sullivan,16
Neil Finer,17 Wade Rich,17 Beverly S. Brozanski,18 John van den Anker,19 Jeffrey Blumer,20 Matthew Laughon,21
Kevin M. Watt,1 Gregory L. Kearns,22,23,24 Edmund V. Capparelli,25 Karen Martz,26 Katherine Berezny,2
Daniel K. Benjamin Jr,1,2 and P. Brian Smith1,2; for the Meropenem Study Team
1Department of Pediatrics, Duke University, and 2Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; 3Department of
Pediatrics, James W. Riley Hospital for Children, Indiana University, Indianapolis; 4Department of Pediatrics, Children’s Hospital at Vanderbilt, Vanderbilt
University, Nashville, Tennessee; 5Department of Pediatrics, Doernbecher Children’s Hospital, Oregon Health & Science University, Portland; 6Department of
Pediatrics, University of Alabama at Birmingham; 7Department of Pediatrics, Primary Children’s Medical Center, University of Utah Medical Center, Salt
Lake City; 8Department of Pediatrics, Children’s Hospital of Philadelphia, Pennsylvania; 9Department of Pediatrics, State University of New York Downstate
Medical Center, Brooklyn; 10Department of Pediatrics, University of Florida, Gainesville; 11Division of Infectious Diseases, Children’s Hospital of Orange
County, Orange, California; 12College of Pharmacy and Department of Pediatrics, University of Michigan, Ann Arbor; 13Department of Pediatrics, University
Hospitals, Cleveland, 14Department of Neonatology, Akron Children’s Hospital, Ohio; 15Department of Pediatrics, Sharp Mary Birch Hospital for Women,
San Diego, California; 16Department of Pediatrics, University of Louisville and Kosair Children’s Hospital, Louisville, Kentucky; 17Department of Pediatrics,
University of California, San Diego; 18Department of Pediatrics and Department of Obstetrics and Gynecology, Children’s Hospital of Pittsburgh, University
of Pittsburgh School of Medicine, Pennsylvania; 19Department of Pediatrics, Pharmacology and Physiology, Children’s National Medical Center, George
Washington University School of Medicine and Health Sciences, Washington, D.C. 20Department of Pediatrics, The University of Toledo, Ohio;
21Department of Pediatrics, The University of North Carolina at Chapel Hill; 22Department of Pediatrics, University of Missouri–Kansas City School of
Medicine, and the Divisions of 23Neonatology and Pediatric Pharmacology, and 24Medical Toxicology, Children’s Mercy Hospital, Kansas City, Missouri;
25Department of Pediatric Pharmacology, University of California, San Diego; and 26EMMES Corporation, Rockville, Maryland
(See the Editorial Commentary by Jacqz-Aigrain, on pages 1503–4.)
Background. Intra-abdominal infections are common in young infants and lead to significant morbidity and
mortality. Meropenem is a broad-spectrum antimicrobial with excellent activity against pathogens associated with
intra-abdominal infections. The purpose of this study was to determine the safety and effectiveness of meropenem
in young infants with suspected or complicated intra-abdominal infections.
Methods. Preterm and term infants <91 days of age with suspected or confirmed intra-abdominal infections
hospitalized in 24 neonatal intensive care units were studied in an open-label, multiple-dose study. Adverse events
and serious adverse events were collected through 3 and 30 days following the last meropenem dose, respectively.
Effectiveness was assessed by 3 criteria: death, bacterial cultures, and presumptive clinical cure score.
Results. Of 200 subjects enrolled in the study, 99 (50%) experienced an adverse event, and 34 (17%) had serious
adverse events; no adverse events were probably or definitely related to meropenem. The most commonly reported
adverse events were sepsis (6%), seizures (5%), elevated conjugated bilirubin (5%), and hypokalemia (5%). Only 2 of
the serious adverse events were determined to be possibly related to meropenem (isolated ileal perforation and an
episode of fungal sepsis). Effectiveness was evaluable in 192 (96%) subjects, and overall treatment success was 84%.
Conclusions. Meropenem was well tolerated in this cohort of critically ill infants, and the majority of infants
treated with meropenem met the definition of therapeutic success.
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Intra-abdominal infections in young infants (<91 days of age)
lead to substantial morbidity and mortality; approximately
20% of infants with necrotizing enterocolitis die, and survivors
suffer from severe neurodevelopmental impairment [1–3].
Consequently, most infants with suspected or confirmed intra-
abdominal infections are treated with empirical antimicrobial
therapy. Broad-spectrum or combination antimicrobial agents
are often prescribed for these infections given their polymicro-
bial nature [4, 5].
Meropenem possesses one of the broadest spectra of antimi-
crobial activity available [6], due to its stability against most
extended-spectrum and AmpC chromosomal β-lactamases.
This property increases the drug’s activity against many
antibiotic-resistant bacteria commonly responsible for life-
threatening infections among young infants [6].
Meropenem is currently approved by the Food and Drug
Administration (FDA) for use in children ≥3 months of age
with bacterial meningitis and/or complicated intra-abdominal
infections; however, there is substantial off-label use of mero-
penem in infants <3 months of age [7] despite the lack of ade-
quate dosing, safety, and efficacy data in this vulnerable group.
Owing to this lack of data and under the Best Pharmaceuticals
for Children Act, the FDA made a formal written request to
obtain needed pediatric information on meropenem. There-
fore, a study was conducted to determine the pharmacokinet-
ics (PK), safety, and effectiveness of meropenem in young
infants with suspected or confirmed intra-abdominal infec-
tions. The PK results of the meropenem study have been pub-




This was an open-label, 24-center, prospective, multidose, PK,
safety, and effectiveness study of meropenem in infants <91
days of age with suspected or confirmed intra-abdominal in-
fection, possible necrotizing enterocolitis, or otherwise receiv-
ing meropenem per local standard of care and likely to survive
>48 hours after enrollment. Participants were excluded for
renal dysfunction (urine output <0.5 mL/hour/kg or serum
creatinine >1.7 mg/dL); history of clinical seizures or electro-
encephalography (EEG)–confirmed seizures; or concomitant
treatment with ertapenem or imipenem. The institutional
review board at each participating center approved this study.
All study participants were enrolled after obtaining informed
consent from a parent or legal guardian. Study procedures
were in accordance with the ethical standards of the Helsinki
Declaration (1964, amended in 2008) of the World Medical
Association.
Administration of Study Drug and Procedures
Subjects were stratified into 4 groups based on gestational age
(GA, <32 weeks and ≥32 weeks) and postnatal age (PNA, <2
weeks and ≥2 weeks) to receive intravenous meropenem: group
1 (GA <32 weeks, PNA <2 weeks), 20 mg/kg body weight every
12 hours; group 2 (GA <32 weeks, PNA ≥2 weeks) and group 3
(GA ≥32 weeks, PNA <2 weeks), 20 mg/kg body weight every 8
hours; and group 4 (GA ≥32 weeks, PNA ≥2 weeks), 30 mg/kg
body weight every 8 hours [8]. During the study, meropenem
was administered to each subject for ≥3 days and ≤21 days.
While the protocol recommended that aminoglycoside therapy
be administered concomitantly with meropenem, treatment
with other antimicrobial agents during the study was deter-
mined by the local standard of care. Blood, urine, or cerebrospi-
nal fluid cultures were obtained as part of routine care.
Safety Assessments
The population evaluated for safety included all participants
who received ≥1 dose of meropenem as part of the study.
Deaths and adverse events (AEs) were assessed in real time by
a clinical events safety committee and an independent data
and safety monitoring board. Specific safety endpoints includ-
ed death, seizures, strictures, perforation, wound dehiscence,
short-gut syndrome, infection with extended β-lactamase–
producing organisms, candidiasis, and antimicrobial therapy
failure. Clinical laboratory values (liver function tests, renal
function tests, blood counts) and vital signs were monitored
weekly if collected as part of the standard of care; laboratory
tests were not collected specifically for study purposes.
All AEs (through 3 days following the last study dose of
meropenem) and all serious adverse events (SAEs; through 30
days following the last dose) were collected. AE causality was
determined by the local investigator as not related, possibly
related, probably related, or definitely related to meropenem.
Additional data were obtained on AEs of special interest: (1)
direct bilirubin >5 mg/dL; (2) indirect bilirubin >15 mg/dL if
<36 weeks postmenstrual age (PMA); (3) indirect bilirubin
>20 mg/dL if ≥36 weeks PMA; (4) aspartate aminotransferase
(AST) increased 10-fold over baseline; (5) alanine aminotrans-
ferase (ALT) increased 10-fold over baseline; (6) serum creati-
nine >2.5 mg/dL; and (7) seizures.
Seizures were recorded and assessed by the local site princi-
pal investigator (PI), and EEGs were evaluated by the site PI
and clinical events safety committee (including a pediatric
neurologist) if they were obtained per local standard of care. If
seizures occurred during meropenem therapy, a blood sample
was collected and meropenem plasma concentrations were
measured. To determine if meropenem concentrations were
associated with seizures, maximum meropenem concentra-
tions at steady state (Cmaxss) were predicted for subjects
with seizures and matched PMA subjects without seizures.
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A 1-compartment structural PK model and individual Baye-
sian PK parameter estimates generated during the population
PK analysis were used for these calculations [8].
Effectiveness Assessments
All participants who underwent an effectiveness assessment
both pre- and postdose were evaluated for effectiveness.
Infants who died during the study period were also considered
in the effectiveness population. Initial clinical status was based
on the presenting signs of each infant and was recorded by
the local PI prior to administration of the first dose of study
meropenem. The same clinical signs and physical findings
were recorded on a subsequent study visit on study day 28 or
≥7 days after treatment ended. The clinical, laboratory, and
radiographic findings used in the presumptive clinical cure
score calculation included mean blood pressure, temperature,
oxygen saturation, serum pH, presence or absence of seizures,
urine output, presence of cardiovascular inotrope support, C-
reactive protein, abdominal girth, and findings on abdominal
radiograph. The overall presumptive clinical cure score was
determined by comparing each criterion in the presumptive
clinical cure scale between the baseline and the final assess-
ment visit. One point was awarded for each criterion if the
subject was asymptomatic at baseline, and the subject re-
mained asymptomatic, had no change, or improved at the ef-
fectiveness visit. One point was also awarded for each
criterion if the subject was symptomatic at baseline and then
was asymptomatic or improved at the effectiveness visit. The
sum of the points assigned to each of the 10 criteria was
assigned as the presumptive clinical cure score.
Success at the effectiveness visit was defined as all of the
following: (1) alive; (2) negative bacterial cultures from sterile
body fluid (except Staphylococcus species); and (3) presump-
tive clinical cure score ≥7. Treatment failure was defined by
any of the following: (1) change in antibiotic therapy while on
study drug with the exception of addition of gram-positive
coverage against culture-confirmed meropenem-resistant or-
ganisms (ie, methicillin-resistant Staphylococcus aureus); (2)
death; or (3) presumptive clinical cure score <7. The antibiotic
change was not a trigger for an effectiveness failure if it was
started on the same day that study meropenem was started or
if the antibiotic was started on the same day that study mero-
penem ended.
Statistical Analysis
This study was not powered to determine effectiveness, and
no inferential statistical tests were performed. The number
and the proportion of subjects who were considered as treat-
ment successes and the number of AEs and proportion of sub-
jects who suffered an AE were determined. Logistic regression
analysis was used to evaluate baseline effectiveness predictors
of SAEs, level II AEs, seizures, and death. This analysis was
adjusted for GA, PNA, sex, and birth weight. No inferential
statistics were performed on laboratory values collected during
the study because laboratory values were recorded only if ob-
tained per standard clinical care, and there was no placebo
arm for comparison. Wilcoxon rank sum test was used to
compare predicted meropenem Cmaxss between subjects with
and without seizures.
RESULTS
Two hundred subjects were enrolled; 142 (71%) were born at
<32 weeks GA, and 130 (65%) were ≥2 weeks PNA at the
time of enrollment (Table 1). The median PNA for the safety
population was 21 days (range 1–92), median GA 27.8 weeks
(range 22.5–40.0), median birth weight 1080 g (range 330–
4768); 59% of the subjects were male, and 65% were white. All
subjects were included in the safety evaluation. Overall, 89%
of subjects had respiratory conditions, 90% a gastrointestinal
condition, and 73% cardiovascular conditions at baseline.
Forty-five percent of subjects had abdominal surgery prior to
enrollment. Thirty-eight percent received meropenem per
routine medical care prior to enrollment.
Indications for meropenem administration included stage II
or higher necrotizing enterocolitis based on Bell’s criteria
(31%), spontaneous intestinal perforation (11%), perforation/
peritonitis (10%), stage I necrotizing enterocolitis (17%), and
receipt of meropenem as part of the standard of care (33%).
Baseline radiography was performed in 174 (87%) subjects
and was normal in 17 (10%) cases. The most commonly ad-
ministered concomitant medications were vancomycin (53%),
gentamicin (51%), furosemide (46%), caffeine citrate (37%),
morphine (36%), fentanyl (35%), midazolam (30%), flucona-
zole (26%), and hydrocortisone (23%). Only 21 (11%) subjects
received meropenem monotherapy.
There were 316 AEs reported in 99 (50%) subjects
(Table 2). Group 1 (<32 weeks GA and <2 weeks PNA) sub-
jects suffered an AE in 26 of 39 (67%) of cases. Twenty-one
(11%) infants had 30 AEs that were determined to be possibly
related to meropenem, and no subjects had an AE that was
probably or definitely related to meropenem. AEs possibly
related to meropenem included coagulopathy (n = 1), sponta-
neous ileal perforation (n = 1), infusion site extravasation
(n = 1), sepsis (n = 3), fungal skin infection (n = 1), elevated
AST (n = 1), elevated direct bilirubin (n = 4), elevated triglyc-
erides (n = 1), hypoglycemia (n = 1), elevated creatinine or
acute renal failure (n = 2), osteopenia (n = 1), skin breakdown
(n = 1), rash (n = 1), acute respiratory failure or pneumothorax
(n = 2), hypotension (n = 2), and seizures (n = 7).
AEs of special interest were observed in 19 infants: 9 (4%)
infants experienced a laboratory event of special interest, and
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seizures were reported in 10 (5%) infants (Table 2). All infants
with laboratory AEs of special interest were <32 weeks GA,
and these AEs included 5 elevated conjugated bilirubin levels,
3 elevated serum creatinine levels, and 1 elevated AST level.
Four (10%) subjects <32 weeks GA and <2 weeks PNA, 3
(3%) subjects <32 weeks GA and ≥2 weeks PNA, 1 (3%)
subject ≥32 weeks GA and <2 weeks PNA, and 2 (7%) sub-
jects ≥32 weeks GA and ≥2 weeks PNA had clinically appar-
ent seizures. Six of 10 subjects had EEG performed, but only 1
(10%) of the 10 seizures was confirmed by EEG. Of the 10
subjects who developed seizures, 1 (10%) was not receiving
study drug on the day of the seizure, 5 (50%) had history of
intraventricular hemorrhage, and 2 (20%) had a plasma
sample obtained for quantitation of meropenem within 4
hours of the event (Table 3). On average, predicted merope-
nem Cmaxss in subjects with seizures did not differ from
those subjects without seizures (mean ± SD: 57.18 [±13.50] vs
53.12 [±5.08] mg/L; P = .24; Table 3).
Thirty-six SAEs were reported in 34 (17%) infants. SAEs
were most commonly reported among infants <32 weeks GA
and <2 weeks PNA (9/39 [23%]; Table 2). Only 2 (6%) of the
SAEs were determined to be possibly related to study drug
Table 1. Subject Demographics
GA <32 Weeks GA ≥32 Weeks
TotalPNA <2 Weeks PNA ≥2 Weeks PNA <2 Weeks PNA ≥2 Weeks
No. 39 103 31 27 200
Gestational age (weeks), median (range) 26.0 (22.5–31.5) 26.3 (23.0–31.5) 36.0 (32.1–40.0) 34.4 (32.0–40.0) 27.8 (22.5–40.0)
Postnatal age (days), median (range) 9 (1–13) 32 (14–92) 6 (1–14) 26 (14–82) 21 (1–92)
Male sex, No. (%) 24 (62) 56 (54) 22 (71) 16 (59) 118 (59)
Hispanic or Latino ethnicity, No. (%) 5 (13) 16 (16) 4 (13) 3 (11) 28 (14)
Race, No. (%)
African-American 12 (31) 33 (32) 8 (26) 6 (22) 59 (30)
White 26 (67) 65 (63) 21 (68) 18 (67) 130 (65)
Other 2 (5) 5 (5) 2 (6) 4 (15) 13 (7)
Abbreviations: GA, gestational age; PNA, postnatal age.
Table 2. Overall Safety Summary










No. 39 103 31 27 200
No. with at least 1 AE 26 (67) 47 (46) 13 (42) 13 (48) 99 (50)
AE by causality
Unrelated 19 (49) 37 (36) 12 (39) 10 (37) 78 (39)
Possibly related 7 (18) 10 (10) 1 (3) 3 (11) 21 (11)
Seizure 4 (10) 3 (3) 1 (3) 2 (7) 10 (5)
Level II laboratory AEa 2 (5) 7 (7) 0 (0) 0 (0) 9 (5)
AST increased 0 (0) 1 (1) 0 (0) 0 (0) 1 (1)
Direct bilirubin increased 2 (5) 3 (3) 0 (0) 0 (0) 5 (3)
Serum creatinine increased 0 (0) 3 (3) 0 (0) 0 (0) 3 (2)
No. with at least 1 SAE 9 (23) 18 (18) 2 (7) 5 (19) 34 (17)
Death 3 (8) 8 (8) 0 (0) 0 (0) 11 (6)
AE that led to study
drug discontinuation
1 (3) 3 (3) 0 (0) 2 (7) 6 (3)
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GA, gestational age; PMA, postmenstrual age; PNA,
postnatal age; SAE, serious adverse event.
a Level II laboratory AE: direct bilirubin >5 mg/dL; indirect bilirubin >15 mg/dL if <36 weeks PMA; indirect bilirubin >20 mg/dL if ≥36 weeks PMA; AST increased
10-fold over baseline; ALT increased 10-fold over baseline; and serum creatinine >2.5 mg/dL.
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(isolated ileal perforation and an episode of fungal sepsis).
Eleven infants (6%) in the study died. All deaths occurred in
infants <32 weeks GA: 3 of 39 (8%) in the PNA <2 weeks
group and 8 of 103 (8%) in the PNA ≥2 weeks group. Two of
the subjects of PNA <2 weeks died of multiorgan failure, and
1 died from subarachnoid hemorrhage. Of the 8 deaths in the
PNA ≥2 weeks group, 2 had multiorgan failure, and 1 each
died of pulmonary hemorrhage, intestinal perforation, con-
genital diaphragmatic hernia, respiratory failure, presumed
meningitis, and presumed bacterial sepsis. None of the deaths
were considered related to meropenem.
The most commonly reported AEs were sepsis (6%), seizures
(5%), elevated conjugated bilirubin (5%), and hypokalemia (5%;
Table 4). There were no reports of strictures, development of
short-gut syndrome, or extended-spectrum β-lactamase (ESBL)
infections during administration of meropenem or in the
follow-up period. Eight (4%) infants developed candidiasis, 4
(2%) had perforations, and 4 (2%) had wound dehiscence
during the study period. On average, serum creatinine, AST, and
ALT obtained per routine medical care remained stable
(Table 5). We observed an increasing trend in alkaline phospha-
tase and direct bilirubin values during the study period.


















1 Yes 2 24 … 60.71 47.42 (11.54)
2 Yes 2 25 … 63.08 57.34 (14.41)
3 Yes 8 26 4.84 52.73 54.66 (17.20)
4 Yes 0 26 … 50.83 54.66 (17.20)
5 Yes 10 27 … 40.85 54.32 (7.26)
6 No … 30 … 61.90 52.63 (20.50)
7 Yes 2 30 … 69.61 52.63 (20.50)
8 Yes 1 35 14.93 74.07 52.92 (18.90)
9 Yes 14 36 … 67.32 61.64 (22.14)
10 Yes 9 39 … 30.67 42.95 (10.75)
Abbreviations: Cp, meropenem plasma concentration; Cpmaxss, predicted meropenem maximum concentration at steady state.
a Data are mean (standard deviation).
Table 4. Frequently Occurring (≥5 Participants) Adverse Events










No. 39 103 31 27 200
AST increaseda 0 (0) 3 (3) 0 (0) 2 (7) 5 (3)
Atelectasis 2 (5) 0 (0) 0 (0) 3 (11) 5 (3)
Conjugated bilirubin increaseda 5 (13) 3 (3) 0 (0) 1 (4) 9 (5)
Hyperglycemiaa 2 (5) 2 (2) 1 (3) 0 (0) 5 (3)
Hypoglycemiaa 3 (8) 2 (2) 0 (0) 0 (0) 5 (3)
Hypokalemiaa 2 (5) 6 (6) 0 (0) 1 (4) 9 (5)
Hypotensiona 1 (3) 5 (5) 0 (0) 0 (0) 6 (3)
Patent ductus arteriosus 4 (10) 1 (1) 0 (0) 1 (4) 6 (3)
Retinopathy of prematurity 0 (0) 5 (5) 0 (0) 0 (0) 5 (3)
Sepsis 5 (13) 5 (5) 1 (3) 1 (4) 12 (6)
Seizures 4 (10) 3 (3) 1 (3) 2 (7) 10 (5)
Vomiting 0 (0) 1 (1) 4 (13) 0 (0) 5 (3)
Abbreviations: AST, aspartate aminotransferase; GA, gestational age; PNA, postnatal age.
a Defined per the local site.
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Effectiveness was evaluable in 192 (96%) subjects. Overall
success for effectiveness in this population was 84% (162/192;
Table 6). Mortality prior to the effectiveness assessment was 8
of 192 (4%). None of the 50 infants with GA ≥32 weeks died
prior to the effectiveness visit. Success was lowest among
infants <32 weeks GA and <2 weeks PNA (29/39 [74%]) and
highest among infants ≥32 weeks GA in both PNA groups
(51/55 [93%]). Change in antibiotic therapy was the most
common treatment failure surrogate (23/30 [77%]). Of the 23
infants with changes in antibiotic therapy, 2 (10%) had posi-
tive peritoneal fluid cultures while receiving meropenem (Es-
cherichia coli and organism not specified). One hundred
seventeen subjects had 262 cultures (184 blood, 44 urine, 19
cerebrospinal fluid, 14 peritoneal, 1 missing) obtained in the 7
days prior to the first dose of meropenem; 29 had a positive
culture. Of 262 cultures obtained, 40 were positive (27 blood,
8 urine, 5 peritoneal): 75% gram-negative rods, 20% gram-
positive cocci, and 5% gram-positive rods. No study subjects
were blood culture positive for nonstaphylococcal species after
initiation of meropenem therapy.
DISCUSSION
Meropenem is commonly used off-label in infants <3 months
of age, despite a lack of safety and efficacy data, because of its
broad range of antimicrobial activity and its stability against
chromosomally encoded and plasmid-mediated ESBL infec-
tions [9]. Meropenem’s spectrum includes Enterobacteriaceae,
Pseudomonas aeruginosa [6], methicillin-sensitive S. aureus,
Enterococcus faecalis [6], and Bacteroides fragilis [10]. Despite
the benefits associated with meropenem’s extended
Table 6. Effectiveness Results










Evaluable for effectiveness, No. 39 98 28 27 192
Effectiveness success 29 (74) 82 (84) 26 (93) 25 (93) 162 (84)
Deatha 3 (8) 5 (5) 0 (0) 0 (0) 8 (4)
Presumptive clinical cure score ≥7 35 (90) 90 (92) 27 (96) 27 (100) 179 (93)
Presumptive clinical cure score <7 0 (0) 1 (1) 0 (0) 0 (0) 1 (1)
Presumptive clinical cure score missing 4 (10) 7 (7) 1 (4) 0 (0) 12 (6)
Change in antibiotic therapy 7 (18) 12 (12) 2 (7) 2 (7) 23 (12)b
Cultures negative for bacteria 27 (69) 49 (50) 9 (32) 13 (48) 98 (51)
Cultures not done 12 (31) 49 (50) 19 (68) 14 (52) 94 (49)
Abbreviations: GA, gestational age; PNA, postnatal age.
a Death occurring ≤7 days from end of study meropenem.
b Of the 23 participants with change in antibiotic therapy, 1 also died and 1 had a presumptive clinical cure score <7.
Table 5. Laboratory Evaluations
Baseline Days 1–7 Days 8–14 Days 15–21 Days 22–28
Serum creatinine (No.) 181 173 127 85 53
Median (range), mg/dL 0.5 (0.1–1.9) 0.4 (0.0–3.1) 0.4 (0.0–2.7) 0.3 (0.0–2.9) 0.3 (0.0–2.0)
AST (No.) 60 78 68 55 32
Median (range), U/L 37 (12–3358) 33 (9–419) 33 (11–308) 40 (15–567) 50 (19–788)
ALT (No.) 60 80 69 55 30
Median (range), U/L 25 (4–956) 18 (5–140) 16 (4–131) 20 (5–605) 27 (8–168)
Alkaline phosphatase (No.) 64 86 65 52 28
Median (range), U/L 255 (72–1368) 244 (35–967) 321 (104–1103) 412 (101–1600) 508 (123–1145)
Direct bilirubin (No.) 70 71 52 34 14
Median (range), mg/dL 0.6 (0.0–10.8) 0.8 (0.0–10.3) 1.5 (0.0–10.7) 1.7 (0.1–8.5) 3.7 (0.2–6.0)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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antimicrobial spectrum, there are safety concerns related to
potential central nervous system (CNS) side effects in young
infants.
The potential for adverse CNS effects of meropenem, par-
ticularly seizures, has been carefully studied in older children
[11, 12]. In a randomized trial of meropenem or cefotaxime
for bacterial meningitis in children, seizures were reported in
12% (15/129) of the meropenem cohort and 17% (22/129) of
the cefotaxime cohort [13]. None of the seizures were thought
to be related to antibiotic therapy. In the present trial, clinical
seizures were reported in 10 (5%) infants; however, only 1 was
confirmed by EEG, and none were thought to be probably or
definitely related to meropenem by the site PI. Additionally,
50% of infants with seizures had a CNS condition that could
be responsible for the seizures, and we observed no apparent
difference in predicted meropenem plasma concentrations in
patients with or without seizures. Because a comparator arm
was not included in this trial and the number of study partici-
pants was relatively small from an epidemiologic standpoint, it
is difficult to know if the rate of seizures associated with mer-
openem is above the background seizure rate for this popula-
tion. However, among infants admitted to the neonatal
intensive care unit, seizure rates of 9% have been previously
reported [14], and the cumulative incidence in the most pre-
mature infants (<28 weeks GA) is as high as 12%. The majori-
ty (>70%) of infants enrolled in this study were <32 weeks GA
and critically ill at baseline, which suggests that the seizure
rate observed is similar or lower than that reported in prior
studies.
The most commonly reported adverse effects of meropenem
from previously published pediatric studies are diarrhea
(3.3%–4.7%), nausea and vomiting (0.4%–1%), rash (0.8%),
glossitis (1%), and oral thrush (1.9%) [11]. In comparison
trials, these reactions occurred with similar frequency in the
comparison (cephalosporin) group [11, 12]. In our cohort,
there were no reports of diarrhea, glossitis, or oral thrush.
Only 1 (0.5%) subject was reported to have a rash. Vomiting
was reported in 5 (2.5%) infants in this study.
In a review of 6154 patients receiving meropenem in 54
clinical trials (>900 children), meropenem demonstrated a
favorable safety profile relative to comparators including ceph-
alosporins, imipenem/cilastatin, and clindamycin/aminoglyco-
side [15]. Children were given 10–40 mg/kg every 8 hours in
the studies reviewed. The incidence of seizures among all sub-
jects was 0.37%, 0.25%, 0.43%, and 0.38% in the meropenem,
cephalosporin, imipenem/cilastatin, and clindamycin/amino-
glycosides groups, respectively. This finding is not surprising
given that meropenem has less affinity than imipenem for
γ-aminobutyric acid receptors—the potential target for CNS
adverse effects—and has been found to cause less neurotoxici-
ty than imipenem both in animal models and during clinical
trials [11, 16]. In addition, among subjects who received mer-
openem, elevated ALT, AST, alkaline phosphatase, and biliru-
bin levels were observed in 5.2%, 4.3%, 2.2%, and 0.7%,
respectively [15]. In our study, elevation in alkaline phospha-
tase levels was reported as an AE in 1% of subjects. The trend
toward higher alkaline phosphatase and direct bilirubin levels
observed in laboratory values collected throughout this trial as
standard of care (Table 5) may be explained by selectively ob-
taining liver function tests only in infants with previously ab-
normal values or in infants suspected of having abnormal
values. Also, many of the infants in this trial were receiving
total parenteral nutrition, which may lead to cholestasis [17].
Gastrointestinal complications comprise another potential
concern associated with broad-spectrum antimicrobial treat-
ment of neonates. Addition of anaerobic antibiotic coverage
has been associated with the development of strictures in a
cohort of infants with necrotizing enterocolitis [4]. However,
no strictures were reported in this cohort, although our
follow-up for strictures was limited to observation through 30
days following the last dose of meropenem.
In conclusion, meropenem was well tolerated in the cohort
of critically ill infants with suspected and/or proven intra-
abdominal infection. Although our study was not randomized,
the overall success rate was 84% (162/192), meeting the defini-
tion of therapeutic success. The success rate was highest in
more mature infants (≥32 weeks GA; 93% [51/55]). Serious
adverse events probably or definitely associated with merope-
nem were not observed. Collectively, these data support and
may inform the development of comparative trials of merope-
nem in infants with complicated intra-abdominal infections.
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